tiprankstipranks
Company Announcements

Roquefort Therapeutics Secures Key European Patent

Roquefort Therapeutics Secures Key European Patent

Roquefort Investments PLC (GB:ROQ) has released an update.

Roquefort Therapeutics has been granted a European patent for its innovative Mesodermal Killer (MK) cell therapy, applicable in 39 countries, which promises to enhance immunotherapy treatments in oncology and immunology. The company is progressing in pre-clinical development, showing promising results in activating Natural Killer cells, potentially leading to more effective treatments. Additionally, Roquefort Therapeutics is advancing out-licensing deals for its Midkine antibody portfolio and STAT-6 siRNA program, indicating a potentially transformational period ahead.

For further insights into GB:ROQ stock, check out TipRanks’ Stock Analysis page.

Questions or Comments about the article? Write to editor@tipranks.com

Questions or Comments about the article? Write to editor@tipranks.com
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App